Clinical trial NCT04874831: Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
Official title: A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Merkel Cell Carcinoma
Lead sponsor: 4SC AG
Sponsor class: INDUSTRY
Collaborators: name: Merck KGaA, Darmstadt, Germany
First posted: 2021-05-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma


Eligibility criteria: Inclusion Criteria:

1. Signed written informed consent.
2. Age 18 years at signature of Informed Consent Form (ICF).
3. Histologically proven MCC.

   * Confirmation of the diagnosis by immune-histochemistry as per standard at the institution, including (but not limited to) CK20 and TTF-1.
   * Patients must have metastatic or distally recurrent disease; Ml status must be confirmed at entry.
   * Patients must not have received any prior systemic treatment for metastatic MCC. Prior treatment in the adjuvant setting (no clinically detectable disease; no metastatic disease) will be allowed, if the end of the treatment occurred at least 6 months prior to study entry, i.e. signing ICF.
4. Fresh biopsy or archival tumor tissue (not older than 3 months) from an unirradiated lesion.
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry.
6. Estimated life expectancy of more than 12 weeks.
7. Disease must be measurable with at least one unidimensional measurable lesion by RECIST vl.l (including skin lesions).
8. Adequate hematological and organ function defined by the following parameters:

   Adequate hematological function defined by
   * White blood cell count (WBC) \> 3000/pl
   * Absolute Neutrophil Count (ANC) \> 1500/pl
   * Lymphocyte count \> 500/pl
   * Hemoglobin (Hb) \> 9 g/dl (or \> 5.6 mmol/L), may have been transfused
   * Platelet count \> 100.000/pl

   Adequate hepatic function defined by
   * Serum total bilirubin \< 1.5 x ULN
   * ALT and/or AST \< 1.5 x ULN

   Adequate renal function defined by

   • eGFR \> 60 ml/ min (as per Cockcroft-Gault formula)
9. Highly effective contraception for both male and female subjects if the risk of conception exists. Female patients of childbearing potential must have a negative urine or serum pregnancy test before receiving the first dose of study medication and must comply with contraception methods as requested by the study protocol.

Exclusion Criteria:

1. Participation in another interventional clinical study within the past 30 days (participation in observational studies is permitted)
2. Concurrent treatment with a non-permitted drug.
3. Prior therapy with any histone deacetylase (HDAC) inhibitor or antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as anti-programmed death 1 (PD-1), antiprogrammed death-ligand 1 (PD-L1) or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody.
4. Concurrent anti-cancer treatment (for example, cytoreductive therapy, radiotherapy, immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the study treatment.
5. Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from surgery.
6. Concurrent systemic therapy with steroids or other immunosuppressive agents (e.g. methotrexate, azathioprine, interferons, mycophenolate, anti-TNF agents and other), or the use of any investigational drug within 28 days before the start of study treatment. Short-term administration of systemic steroids e.g. for allergic reactions or the management of immune-related adverse events \[irAE\] while on study is allowed. Also, patients requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for purpose of hormonal replacement and at doses \< 10 mg or equivalent prednisone per day.
7. Conditions requiring systemic anti-arrhythmic therapy known to prolong QT/QTc interval, patients with QTcF interval \>480 msec on at least 2 separate and consecutive ECGs at screening or a medical history of long-QT-Syndrome.
8. Patients with active central nervous system (CNS) metastases are excluded and a brain CT/MRI will be required during screening if not performed within 6 weeks prior to the planned start of the study treatment. Subjects with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.
9. History of or concurrent malignancies, except the malignancy is clinically insignificant, no systemic treatment is or has been required for the last 6 months, and the patient is clinically stable
10. Prior organ transplantation (including allogeneic stem-cell transplantation).
11. Any active gastrointestinal disorder that could interfere with the absorption of domatinostat characterized by malabsorption or inability to swallow tablets as per judgment of the Investigator.
12. Positive testing for HIV or known AIDS or HBV or HCV infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening is positive).
13. Active or history of any autoimmune disease (except for patients with vitiligo) or immune-diseases that required treatment with systemic immune modulating drugs.
14. History or current evidence of clinically relevant allergies or hypersensitivity, which includes known or suspected intolerabilities attributed to domatinostat or avelumab or to constituents of the domatinostat tablets or avelumab infusion and known severe hypersensitivity reactions (Grade 3) to monoclonal antibodies.
15. Persisting toxicity related to prior therapy Grade \> 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0; however, sensory neuropathy Grade \< 2 will be acceptable.
16. Pregnancy or lactation period.
17. Known or suspected alcohol or drug abuse.
18. Clinically significant (i.e. active) cardiovascular and/or thromboembolic diseases:

    * Cerebral vascular accident or stroke \< 6 months prior to enrollment.
    * Uncontrolled hypertension
    * Congestive heart failure (New York Heart Association (NYHA) ClassIII or IV)
    * Serious cardiac arrhythmia requiring medication (patients with status post pacemaker and/or defibrillator implantation can be included)
    * Symptomatic ischemic or severe valvular heart disease
    * Unstable angina pectoris or a myocardial infarction within 6 months prior to screening, i.e. signing ICF
19. All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient s tolerance to the study treatment.
20. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
21. Legal incapacity or limited legal capacity.
22. Administration of a live vaccine within 28 days prior to study drug administration. Live vaccines are also prohibited during study treatment.

Primary outcomes:
measure: Confirmed Objective Response (OR)
timeFrame: up to 1 year
Secondary outcomes:
measure: Duration of Response (DOR)
timeFrame: up to 1 year
measure: Durable Response (DR)
timeFrame: up to 1 year
measure: Overall Survival (OS)
timeFrame: approx 3.5 years
measure: Progression Free Survival (PFS)
timeFrame: approx. 3 years
measure: Disease Control (DC)
timeFrame: up to 1 year
measure: RECIST vl.l response
timeFrame: up to 1 year
measure: Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0
timeFrame: approx. 3 years
measure: Correlation of biomarker expression to efficacy
timeFrame: up to 1 year
measure: Anti-drug-antibodies (ADAs)
timeFrame: up to 1 year
measure: Health related Quality of Life determined by the questionnaire FACT-M
timeFrame: up to 1 year
measure: Plasma concentration of domatinostat and avelumab
timeFrame: up to 1 year
measure: Health related Quality of Life determined by the questionnaire EQ-5D-5L
timeFrame: up to 1 year
Other outcomes:
Locations:
Study officials:
References: